Oncology software assets change hands

Article

Varian Medical Systems has acquired the assets of Denver-based OpTx, a privately held supplier of software for medical oncology practices. Varian, which paid approximately $18 million cash to obtain the assets, plans to continue to develop, sell,

Varian Medical Systems has acquired the assets of Denver-based OpTx, a privately held supplier of software for medical oncology practices. Varian, which paid approximately $18 million cash to obtain the assets, plans to continue to develop, sell, install, and service OpTxTools software worldwide as a stand-alone product for medical oncology practices and as part of its VARiS software for coordination with radiation oncology. With this acquisition, Varian is able to offer an integrated single software system for managing and coordinating radiation therapy and chemotherapy routinely used in the treatment of cancer, according to the company. The acquisition is expected to add annualized revenues of $9 million to Varian coffers and be nearly neutral to earnings for the company in fiscal year 2004.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.